8-K current report · filed Jul 24, 2026

Surgery Partners, Inc. (SGRY) 8-K Current Report: July 24, 2026

Item 1.01Item 7.01Item EX-99.1SGRY overview

Short answer

Surgery Partners, Inc. (SGRY) filed an 8-K current report with the SEC on July 24, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Intermountain Health agreed to acquire Mountain View Hospital and Idaho Falls Community Hospital for approximately $1.15 billion.

Surgery Partners, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Intermountain Health agreed to acquire Mountain View Hospital and Idaho Falls Community Hospital for approximately $1.15 billion
  • Surgery Partners expects approximately $795 million in total consideration, subject to indebtedness, working capital, expenses, and closing adjustments
  • Final net cash proceeds remain uncertain pending customary purchase price adjustments
  • Closing depends on physician approvals, Hart-Scott-Rodino clearance, regulatory approvals, and third-party consents
  • Either party may terminate if closing does not occur within 60 days after escrowed signatures are released

Item 7.01 · Regulation FD Disclosure

  • Surgery Partners agreed to sell its Idaho Falls facility interests to Intermountain Health
  • Transaction signals portfolio rationalization and potential shift away from Idaho Falls operations
  • Press release furnished as Exhibit 99.1 contains the transaction’s substantive terms
  • Disclosure is furnished under Regulation FD, limiting Section 18 liability and automatic Securities Act incorporation

Item EX-99.1 · Exhibit EX-99.1

  • Proposed sale of Idaho Falls facilities to Intermountain Health values assets at approximately $1.15 billion
  • Surgery Partners’ consideration approximately $795 million, with final net cash proceeds subject to closing adjustments
  • Portfolio optimization would simplify operations and provide substantial liquidity, but physician, regulatory and third-party approvals remain outstanding
  • 2026 guidance reaffirmed excluding transaction impact: revenue $3.35–$3.45 billion and Adjusted EBITDA at least $530 million
  • Transaction expected to close in coming months, with financial outlook impact to be disclosed after completion

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Surgery Partners, Inc. 8-K filings

Get the next SGRY 8-K as it lands

Follow SGRY for push alerts, or ask the research agent what this filing means.